<p>ADC Therapeutics SA（纽约证券交易所代码：ADCT - 获取免费报告）在周四的午盘交易中下跌了 4.5%。该公司的股价最低曾达到 3.88 美元，最后交易价为 3.9050 美元。当天交易了约 740,786 股，较 659,677 股的日均交易量增加了 12%。该股票此前收盘价为 4.09 美元。</p>
<p>获取 <strong>ADC Therapeutics</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<p>几位股票分析师最近对 ADCT 股票发表了看法。HC Wainwright 将 ADC Therapeutics 的目标股价从 8.00 美元下调至 7.00 美元，并在 10 月 16 日的研究报告中对该股票给予了 “买入” 评级。Weiss Ratings 在 1 月 21 日的研究报告中重新发布了对 ADC Therapeutics 的 “卖出（d-）” 评级。加拿大皇家银行在 12 月 3 日的报告中重申了 “跑赢大盘” 评级，并对 ADC Therapeutics 的股票设定了 5.00 美元的目标价。华尔街 Zen 在 11 月 15 日的报告中将 ADC Therapeutics 的评级从 “卖出” 上调至 “持有”。最后，Guggenheim 在 11 月 12 日的研究报告中重新发布了 “买入” 评级，并对 ADC Therapeutics 的股票设定了 10.00 美元的目标价。五位股票研究分析师对该股票给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均目标价为 7.50 美元。</p>
<p><strong>阅读我们对 ADC Therapeutics 的最新股票分析</strong></p>
<h2>ADC Therapeutics 股票下跌 4.5%</h2>
<p>该公司的市值为 4.8374 亿美元，市盈率为-2.69，贝塔值为 1.93。该公司的 50 日简单移动平均线为 3.73 美元，200 日简单移动平均线为 3.67 美元。</p>
<p>ADC Therapeutics（纽约证券交易所代码：ADCT - 获取免费报告）最近在 11 月 10 日公布了其季度财报。该公司报告每股收益为（0.30 美元），超出市场共识预期的（0.40 美元）0.10 美元。该公司季度收入为 1643 万美元，而市场共识预期为 1708 万美元。整体来看，分析师预测 ADC Therapeutics SA 在本年度的每股收益将为-1.69 美元。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者和对冲基金最近买入和卖出了该公司的股票。R Squared Ltd 在第三季度购买了 ADC Therapeutics 的新股份，价值 59,000 美元。Henrickson Nauta Wealth Advisors Inc.在第四季度购买了 ADC Therapeutics 的新股份，价值 69,000 美元。SG Americas Securities LLC 在第四季度购买了 ADC Therapeutics 的新股份，价值约 86,000 美元。Creative Planning 在第二季度购买了 ADC Therapeutics 的新股份，价值约 96,000 美元。最后，Ethic Inc.在第二季度购买了 ADC Therapeutics 的新股份，价值约 103,000 美元。41.10% 的股票由机构投资者持有。</p>
<h2>关于 ADC Therapeutics</h2>
<p>（获取免费报告）</p>
<p>ADC Therapeutics SA 是一家临床阶段的生物制药公司，专注于发现和开发高度靶向的抗体药物偶联物（ADCs），旨在治疗如非霍奇金淋巴瘤和急性髓性白血病等血液恶性肿瘤。通过将单克隆抗体的特异性与强效细胞毒性药物结合，该公司旨在最大限度地消灭肿瘤细胞，同时限制非靶向毒性。</p>
<p>ADC Therapeutics 产品组合的核心是 loncastuximab tesirine-lpyl，这是一种针对 CD19 的 ADC，已获得美国的加速批准。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票而非 ADC Therapeutics</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>曝光：“29% 账户”</li>
<li>用这四个简单步骤 “防止” 你的银行账户受到影响</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>错过了 Nvidia？你接下来的 12 个月窗口</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 ADC Therapeutics 吗？</h2>
<p>在你考虑 ADC Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 ADC Therapeutics 并不在名单上。</p>
<p>虽然 ADC Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

医疗业 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

<p>ADC Therapeutics（纽约证券交易所代码：ADCT）股票在午盘交易中下跌 4.5%，报$3.9050，成交量为 740,786 股。分析师的评级意见不一，HC Wainwright 将其目标价从$8.00 下调至$7.00，但维持 “买入” 评级。该公司报告的季度每股亏损为 ($0.30)，超出预期，但收入为 1643 万美元，低于预期。机构投资者持有该股票的 41.10%，分析师的平均目标价为$7.50，表明共识评级为 “适度买入”</p>

<p>ADC Therapeutics SA (NYSE:ADCT - Get Free Report) was down 4.5% during mid-day trading on Thursday . The company traded as low as $3.88 and last traded at $3.9050. Approximately 740,786 shares were traded during trading, an increase of 12% from the average daily volume of 659,677 shares. The stock had previously closed at $4.09.</p>
<div class="lb-trans"><p>ADC Therapeutics SA（纽约证券交易所代码：ADCT - 获取免费报告）在周四的午盘交易中下跌了 4.5%。该公司的股价最低曾达到 3.88 美元，最后交易价为 3.9050 美元。当天交易了约 740,786 股，较 659,677 股的日均交易量增加了 12%。该股票此前收盘价为 4.09 美元。</p>
</div><p>Get <strong>ADC Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>ADC Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several equities analysts recently weighed in on ADCT shares. HC Wainwright dropped their price target on shares of ADC Therapeutics from $8.00 to $7.00 and set a &#34;buy&#34; rating on the stock in a research report on Thursday, October 16th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of ADC Therapeutics in a research note on Wednesday, January 21st. Royal Bank Of Canada restated an &#34;outperform&#34; rating and issued a $5.00 target price on shares of ADC Therapeutics in a report on Wednesday, December 3rd. Wall Street Zen upgraded ADC Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 15th. Finally, Guggenheim reissued a &#34;buy&#34; rating and issued a $10.00 price target on shares of ADC Therapeutics in a research report on Wednesday, November 12th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $7.50.</p>
<div class="lb-trans"><p>几位股票分析师最近对 ADCT 股票发表了看法。HC Wainwright 将 ADC Therapeutics 的目标股价从 8.00 美元下调至 7.00 美元，并在 10 月 16 日的研究报告中对该股票给予了 “买入” 评级。Weiss Ratings 在 1 月 21 日的研究报告中重新发布了对 ADC Therapeutics 的 “卖出（d-）” 评级。加拿大皇家银行在 12 月 3 日的报告中重申了 “跑赢大盘” 评级，并对 ADC Therapeutics 的股票设定了 5.00 美元的目标价。华尔街 Zen 在 11 月 15 日的报告中将 ADC Therapeutics 的评级从 “卖出” 上调至 “持有”。最后，Guggenheim 在 11 月 12 日的研究报告中重新发布了 “买入” 评级，并对 ADC Therapeutics 的股票设定了 10.00 美元的目标价。五位股票研究分析师对该股票给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均目标价为 7.50 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on ADC Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 ADC Therapeutics 的最新股票分析</strong></p>
</div><h2>ADC Therapeutics Stock Down 4.5%</h2>
<div class="lb-trans"><h2>ADC Therapeutics 股票下跌 4.5%</h2>
</div><p>The firm has a market cap of $483.74 million, a P/E ratio of -2.69 and a beta of 1.93. The firm's 50-day simple moving average is $3.73 and its 200 day simple moving average is $3.67.</p>
<div class="lb-trans"><p>该公司的市值为 4.8374 亿美元，市盈率为-2.69，贝塔值为 1.93。该公司的 50 日简单移动平均线为 3.73 美元，200 日简单移动平均线为 3.67 美元。</p>
</div><p>ADC Therapeutics (NYSE:ADCT - Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.10. The firm had revenue of $16.43 million for the quarter, compared to the consensus estimate of $17.08 million. As a group, analysts forecast that ADC Therapeutics SA will post -1.69 earnings per share for the current year.</p>
<div class="lb-trans"><p>ADC Therapeutics（纽约证券交易所代码：ADCT - 获取免费报告）最近在 11 月 10 日公布了其季度财报。该公司报告每股收益为（0.30 美元），超出市场共识预期的（0.40 美元）0.10 美元。该公司季度收入为 1643 万美元，而市场共识预期为 1708 万美元。整体来看，分析师预测 ADC Therapeutics SA 在本年度的每股收益将为-1.69 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of the business. R Squared Ltd bought a new stake in ADC Therapeutics during the 3rd quarter valued at $59,000. Henrickson Nauta Wealth Advisors Inc. bought a new stake in shares of ADC Therapeutics during the 4th quarter valued at $69,000. SG Americas Securities LLC purchased a new stake in ADC Therapeutics during the 4th quarter worth about $86,000. Creative Planning purchased a new stake in ADC Therapeutics during the 2nd quarter worth about $96,000. Finally, Ethic Inc. bought a new position in ADC Therapeutics in the 2nd quarter worth about $103,000. 41.10% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近买入和卖出了该公司的股票。R Squared Ltd 在第三季度购买了 ADC Therapeutics 的新股份，价值 59,000 美元。Henrickson Nauta Wealth Advisors Inc.在第四季度购买了 ADC Therapeutics 的新股份，价值 69,000 美元。SG Americas Securities LLC 在第四季度购买了 ADC Therapeutics 的新股份，价值约 86,000 美元。Creative Planning 在第二季度购买了 ADC Therapeutics 的新股份，价值约 96,000 美元。最后，Ethic Inc.在第二季度购买了 ADC Therapeutics 的新股份，价值约 103,000 美元。41.10% 的股票由机构投资者持有。</p>
</div><h2>About ADC Therapeutics</h2>
<div class="lb-trans"><h2>关于 ADC Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.</p>
<div class="lb-trans"><p>ADC Therapeutics SA 是一家临床阶段的生物制药公司，专注于发现和开发高度靶向的抗体药物偶联物（ADCs），旨在治疗如非霍奇金淋巴瘤和急性髓性白血病等血液恶性肿瘤。通过将单克隆抗体的特异性与强效细胞毒性药物结合，该公司旨在最大限度地消灭肿瘤细胞，同时限制非靶向毒性。</p>
</div><p>At the core of ADC Therapeutics' portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.</p>
<div class="lb-trans"><p>ADC Therapeutics 产品组合的核心是 loncastuximab tesirine-lpyl，这是一种针对 CD19 的 ADC，已获得美国的加速批准。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than ADC Therapeutics</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>EXPOSED: The “29% Account”</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Missed Nvidia? Your next 12-month window</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非 ADC Therapeutics</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>曝光：“29% 账户”</li>
<li>用这四个简单步骤 “防止” 你的银行账户受到影响</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>错过了 Nvidia？你接下来的 12 个月窗口</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ADC Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 ADC Therapeutics 吗？</h2>
</div><p>Before you consider ADC Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 ADC Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADC Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 ADC Therapeutics 并不在名单上。</p>
</div><p>While ADC Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 ADC Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

ADC Therapeutics (NYSE:ADCT) Stock Price Down 4.5%  - Here's Why

Market Beat

标普全球医疗股指数 ETF - iShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

ADC Therapeutics SA

纽交所高增长板生物技术指数 ETF - First Trust

基因改革 ETF - ARK

生物科技 ETF - VanEck Vectors

Invesco Nasdaq Biotechnology ETF

医药突破 ETF - ALPS

美国制药 ETF - iShares

医疗业 ETF - Vanguard

2 倍做多纳斯达克生物技术 ETF - ProShares

ADC Therapeutics（纽约证券交易所代码：ADCT）股价下跌 4.5% - 以下是原因